Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew J Memoli

Showing results (1-10 of 61) with videos related to

Pageof 7
Sort By:
JAMA|January 17, 2013
Bacterial coinfection in influenza: a grand rounds reviewDaniel S Chertow, Matthew J Memoli
Medrxiv : the Preprint Server for Health Sciences|November 3, 2021
The 1968 Influenza Pandemic and COVID-19 OutcomesCharles A Taylor, Christopher Boulos, Matthew J Memoli
NPJ Vaccines|June 13, 2020
Universal coronavirus vaccines: the time to start is nowLuca T Giurgea, Alison Han, Matthew J Memoli
Drug Discovery Today|July 5, 2008
Pandemic and seasonal influenza: therapeutic challengesMatthew J Memoli, David M Morens, Jeffery K Taubenberger
Influenza and Other Respiratory Viruses|November 23, 2012
Influenza in pregnancyMatthew J Memoli, Hillery Harvey, David M Morens, et al.
Microbiology Spectrum|June 24, 2026
ELISA-based quantification of neuraminidase in commercial influenza vaccines using virus-derived reference antigensHyeog Kang, Jin Gao, Luca Giurgea, et al.
Diagnostic Microbiology and Infectious Disease|March 25, 2011
Detection of seasonal H3N2 influenza A virus by type-specific TaqMan minor groove binder probe assayRuixue Wang, Louis M Schwartzman, Matthew J Memoli, et al.
Vaccines|July 29, 2020
Influenza Neuraminidase: A Neglected Protein and Its Potential for a Better Influenza VaccineLuca T Giurgea, David M Morens, Jeffery K Taubenberger, et al.
Critical Care Medicine|January 6, 2010
The 1918 influenza pandemic: lessons for 2009 and the futureDavid M Morens, Jeffery K Taubenberger, Hillery A Harvey, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 30, 2010
Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hostsMatthew J Memoli, Rachel J Hrabal, Arash Hassantoufighi, et al.
Pageof 7

Showing results (1-10 of 61) with videos related to

Sort By:
Pageof 7
JAMA|January 17, 2013
Bacterial coinfection in influenza: a grand rounds reviewDaniel S Chertow, Matthew J Memoli
Medrxiv : the Preprint Server for Health Sciences|November 3, 2021
The 1968 Influenza Pandemic and COVID-19 OutcomesCharles A Taylor, Christopher Boulos, Matthew J Memoli
NPJ Vaccines|June 13, 2020
Universal coronavirus vaccines: the time to start is nowLuca T Giurgea, Alison Han, Matthew J Memoli
Drug Discovery Today|July 5, 2008
Pandemic and seasonal influenza: therapeutic challengesMatthew J Memoli, David M Morens, Jeffery K Taubenberger
Influenza and Other Respiratory Viruses|November 23, 2012
Influenza in pregnancyMatthew J Memoli, Hillery Harvey, David M Morens, et al.
Microbiology Spectrum|June 24, 2026
ELISA-based quantification of neuraminidase in commercial influenza vaccines using virus-derived reference antigensHyeog Kang, Jin Gao, Luca Giurgea, et al.
Diagnostic Microbiology and Infectious Disease|March 25, 2011
Detection of seasonal H3N2 influenza A virus by type-specific TaqMan minor groove binder probe assayRuixue Wang, Louis M Schwartzman, Matthew J Memoli, et al.
Vaccines|July 29, 2020
Influenza Neuraminidase: A Neglected Protein and Its Potential for a Better Influenza VaccineLuca T Giurgea, David M Morens, Jeffery K Taubenberger, et al.
Critical Care Medicine|January 6, 2010
The 1918 influenza pandemic: lessons for 2009 and the futureDavid M Morens, Jeffery K Taubenberger, Hillery A Harvey, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 30, 2010
Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hostsMatthew J Memoli, Rachel J Hrabal, Arash Hassantoufighi, et al.
Pageof 7